Prevalence of metallo-β-lactamase among Pseudomonas aeruginosa and Acinetobacter baumannii in a Korean University hospital and comparison of screening methods for detecting metallo-β-lactamase

Oh, Eun‐Jee; Lee, Seungok; Park, Yeon-Joon; Park, Jung Jun; Park, Kang-Gyun; Kim, Sang Il; Kang, Moon Won; Kim, Byung Kee

doi:10.1016/s0167-7012(03)00090-3

Cited by 66 publications

(55 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…due to metallo-β-lactamases (MBLs) production have been reported from different regions. [1][2][3] The emergence of these MBLs in gram negative bacilli is becoming a therapeutic challenge as these enzymes possess high hydrolytic activity that leads to degradation of higher generation cephalosporins. Moreover, the treatment alternatives are unavailable, or expensive/toxic with poor outcome.…”

Section: Abstract: Acinetobacter Spp Metallo-β-lactamase Pseudomonmentioning

confidence: 99%

Metallo-β-lactamase-producing clinical isolates of Acinetobacter species and Pseudomonas aeruginosa from intensive care unit patients of a tertiary care hospital

Irfan¹,

Zafar²,

Guhar³

et al. 2008

Indian J Med Microbiol

View full text Add to dashboard Cite

Prompt detection of metallo-β-lactamase (MBL) producing isolates is necessary to prevent their dissemination. Frequency of MBLs producing strains among multidrug resistant (MDR) Acinetobacter species and Pseudomonas aeruginosa was evaluated in critical care patients using imipenem-EDTA disk method. One hundred MDR Acinetobacter spp. and 42 Pseudomonas aeruginosa were checked for MBL production, from January to June 2001. MBL was produced by 96.6 % of imipenem-resistant Acinetobacter isolates, whereas 100% imipenem-resistant Pseudomonas aeroginosa isolates were MBL producers. Carbapenem resistance in MDR Acinetobacter spp. and Pseudomonas aeruginosa isolates in this study was due to MBLs. This calls for strict infection control measures to prevent further dissemination. Key words: Acinetobacter spp, metallo-β-lactamase, Pseudomonas aeruginosaCarbapenem group of antibiotics play a vital role in the management of hospital-acquired gram negative infections, because of their broad spectrum activity and stability to hydrolysis by most of the β-lactamases, including extended spectrum β-lactamases (ESBLs). Nosocomial outbreaks of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. due to metallo-β-lactamases (MBLs) production have been reported from different regions. [1][2][3] The emergence of these MBLs in gram negative bacilli is becoming a therapeutic challenge as these enzymes possess high hydrolytic activity that leads to degradation of higher generation cephalosporins. Moreover, the treatment alternatives are unavailable, or expensive/toxic with poor outcome.[4] Plasmid mediated MBL genes spread rapidly to other species of gram negative bacilli; [5] therefore rapid detection of metallo-ß-lactamases production is necessary to modify therapy and to initiate effective infection control to prevent their dissemination. To date there has been one report from Pakistan suggesting presence of MBL producing isolate.[6] There is however need for a systematic study to assess the extent of this form of resistance amongst our isolates. The purpose of this study was to evaluate the metallo-ß-lactamase (MBL) production among multidrug resistant (MDR) Acinetobacter spp. and Pseudomonas aeruginosa, isolated from clinical specimens of intensive care unit patients. Materials and MethodsThis study was conducted in the clinical microbiology laboratory of The Aga Khan University Hospital, Karachi, Pakistan. One hundred MDR clinical isolates of Acinetobacter species and 42 Pseudomonas aeruginosa were studied for MBL production. These organisms were isolated from respiratory secretions, wound swabs, urine and blood culture specimens of intensive care unit patients, admitted from January to April 2001. A multidrug resistant isolate was deÞ ned as resistance to two or more drugs or drug classes of therapeutic relevance. [7] All the isolates of Pseudomonas aeruginosa were characterised to species level using standard procedures. Similarly, Acinetobacter isolates were characterised to the genus level using these proced...

show abstract

Section: Abstract: Acinetobacter Spp Metallo-β-lactamase Pseudomonmentioning

confidence: 99%

Metallo-β-lactamase-producing clinical isolates of Acinetobacter species and Pseudomonas aeruginosa from intensive care unit patients of a tertiary care hospital

Irfan¹,

Zafar²,

Guhar³

et al. 2008

Indian J Med Microbiol

View full text Add to dashboard Cite

show abstract

“…GIM, VIM, Characterization by phenotypic and genotypic methods of metallo-β-lactamase-producing Pseudomonas aeruginosa isolated from patients with cystic fibrosis SPM and IMP are genes in integrons, which integrate into chromosomes or plasmids (15,16). The genes involved in MBL production are either plasmid-or chromosome-mediated, and are transferred horizontally.…”

Section: Introductionmentioning

confidence: 99%

Characterization by phenotypic and genotypic methods of metallo-β-lactamase-producing Pseudomonas aeruginosa isolated from patients with cystic fibrosis

Zhang

Wang

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract.Pseudomonas aeruginosa continues to be a predominant cause of infections with high intrinsic resistance to antibiotics, resulting in treatment failure. P. aeruginosa is the leading cause of respiratory infections among cystic fibrosis (CF) patients. Resistance to carbapenem antibiotics among P. aeruginosa has been reported. Thus, this study was undertaken to characterize the metallo-β-lactamase (MBL) production of P. aeruginosa by phenotypic and genotypic methods. A total of 572 sputum samples were collected from cystic fibrosis patients along with the patient demographic details in a questionnaire. In total, 217 P. aeruginosa isolates were collected and an antibiogram revealed that 159 (73.3%) and 141 (64.9%) of these colonies exhibited resistance to imipenem and meropenem, respectively. Ceftazidime and tobramycin resistance were both identified in 112 (51.6%) isolates, and resistance to piperacillin-tazobactam, gatifloxacin and netilmicin was detected in 96 (44.2%) respective samples. A total of 62 (28.6%) respective samples were resistant to cefoperazone, cefepime and ceftriaxone. The least antibiotic resistance was shown to amikacin and ceftizoxime with 51 (23.5%) and 32 (14.7%) respective colonies resistant to the antibiotics. The minimum inhibitory concentration (MIC) for imipenem revealed a reduction in the MIC values. MBL screening by the zone enhancement method using ceftazidime plus EDTA discs demonstrated that 63 (56.25%) of the colonies were positive for MBL. A total of 53 (84.1%) samples expressed blaVIM and 48 (76.1%) expressed blaIMP genes, as detected by duplex polymerase chain reaction. In conclusion, carbapenem resistance is of great clinical concern in cystic fibrosis patients with P. aeruginosa infection. Therefore, mandatory regular screening and monitoring the resistance in P. aeruginosa among CF patients is required.

show abstract

“…26 In 2003, research by Oh et al found that there was a 13% prevalence of MBLs in isolates of A. baumannii. 37 These isolates were found to have decreased susceptibility to imipenem and ceftazidime. 37 However, in 2005, a study by Altoparlak et al found that 33% of imipenem-resistant isolates of A. baumannii from a burn wound unit in a hospital in Turkey were MBL producers.…”

mentioning

confidence: 99%

“…37 These isolates were found to have decreased susceptibility to imipenem and ceftazidime. 37 However, in 2005, a study by Altoparlak et al found that 33% of imipenem-resistant isolates of A. baumannii from a burn wound unit in a hospital in Turkey were MBL producers. 38 In 2011, Peymani et al reported the phenotypic detection of MBL producers in 49% (31/63) of A. baumannii isolates in a tertiary hospital in Iran using the MBL E-test.…”

mentioning

confidence: 99%

Prevalence of carbapenem resistance genes inAcinetobacter baumanniiisolated from clinical specimens obtained from an academic hospital in South Africa

Kock

Bellomo

Storm

et al. 2013

Southern African Journal of Epidemiology and Infection

View full text Add to dashboard Cite

Original Research: Prevalence of carbapenem resistance genes in Acinetobacter baumannii isolated from clinical specimens Acinetobacter baumannii is an important cause of hospital-acquired infections. The occurrence of carbapenem resistance that is caused by the carbapenem-hydrolysing class D β-lactamases and the metallo-β-lactamases (MBLs) limits the range of therapeutic alternatives in treating A. baumannii infections. In this study, two multiplex polymerase chain reactions were performed to screen for both carbapenem-hydrolysing class D β-lactamases and MBL genes in 97 clinical isolates of A. baumannii. Oxacillinase (OXA)-51 had a prevalence of 83% (81/97), and OXA-23 had a prevalence of 59% (57/97). One isolate was positive for an MBL [Verona integron-encoded metallo β-lactamases (VIM)]. Therefore, continuous surveillance and monitoring of A. baumannii is crucial because of the high prevalence of antibiotic resistance genes.Peer reviewed.

show abstract

Prevalence of metallo-β-lactamase among Pseudomonas aeruginosa and Acinetobacter baumannii in a Korean University hospital and comparison of screening methods for detecting metallo-β-lactamase

Cited by 66 publications

References 21 publications

Metallo-β-lactamase-producing clinical isolates of <i> Acinetobacter</i> species and <i> Pseudomonas aeruginosa</i> from intensive care unit patients of a tertiary care hospital

Metallo-β-lactamase-producing clinical isolates of <i> Acinetobacter</i> species and <i> Pseudomonas aeruginosa</i> from intensive care unit patients of a tertiary care hospital

Characterization by phenotypic and genotypic methods of metallo-β-lactamase-producing Pseudomonas aeruginosa isolated from patients with cystic fibrosis

Prevalence of carbapenem resistance genes inAcinetobacter baumanniiisolated from clinical specimens obtained from an academic hospital in South Africa

Contact Info

Product

Resources

About